TY - JOUR
T1 - Relapse of Juvenile Idiopathic Arthritis-Associated Uveitis after Discontinuation of Immunomodulatory Therapy
AU - Acharya, Nisha R.
AU - Patel, Sarju
AU - Homayounfar, Gelareh
AU - Enanoria, Wayne T.A.
AU - Shakoor, Akbar
AU - Chakrabarti, Anindita
AU - Goldstein, Debra A.
N1 - Funding Information:
This work was partly supported by a grant from the Doris Duke Charitable Foundation to UCSF to fund Clinical Research Fellow Dr Homayounfar. Dr Enanoria was supported for statistical consulting by That Man May See Foundation, UCSF. The UCSF Department of Ophthalmology is supported by National Eye Institute grant EY06190 and an unrestricted grant from the Research to Prevent Blindness Foundation. Dr Goldstein is supported by unrestricted grant from Research to Prevent Blindness. The sponsors or funding organizations had no role in the design or conduct of this research. This work was partly supported by a grant from the Doris Duke Charitable Foundation to UCSF to fund Clinical Research Fellow Dr Homayounfar. Dr Enanoria was supported for statistical consulting by That Man May See Foundation, UCSF. The UCSF Department of Ophthalmology is supported by National Eye Institute grant EY06190 and an unrestricted grant from the Research to Prevent Blindness Foundation. Dr Goldstein is supported by unrestricted grant from Research to Prevent Blindness. The sponsors or funding organizations had no role in the design or conduct of this research.
Funding Information:
This work was partly supported by a grant from the Doris Duke Charitable Foundation to UCSF to fund Clinical Research Fellow Dr Homayounfar. Dr Enanoria was supported for statistical consulting by That Man May See Foundation, UCSF. The UCSF Department of Ophthalmology is supported by National Eye Institute grant EY06190 and an unrestricted grant from the Research to Prevent Blindness Foundation. Dr Goldstein is supported by unrestricted grant from Research to Prevent Blindness. The sponsors or funding organizations had no role in the design or conduct of this research.
Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.
PY - 2019/5/19
Y1 - 2019/5/19
N2 - Purpose: To assess treatment outcomes in juvenile idiopathic arthritis (JIA)-associated uveitis and relapse rates upon discontinuation of immunomodulatory therapy (IMT). Methods: Medical records of patients with JIA-associated uveitis seen at the University of Illinois at Chicago and the F.I. Proctor Foundation uveitis clinics from September 14, 1988 to January 5, 2011 were reviewed. The main outcome was time to relapse after attempting to discontinue IMT.Results: Of 66 patients with JIA-associated uveitis, 51 (77%) received IMT as either sole or combination therapy. Of a total of 51, 41 (80%) patients achieved corticosteroid-sparing control. Attempts were made to discontinue treatment in 19/51 (37%) patients. Of a total of 19 patients, 13 (68%) attempting to discontinue IMT relapsed, with a median time to relapse of 288 days from the time of attempted taper/discontinuation (IQR: 108–338).Conclusions: Corticosteroid-sparing control of inflammation was achieved in the majority of patients; however, attempts to stop IMT were often unsuccessful. Close follow-up of patients after discontinuation of therapy is warranted.
AB - Purpose: To assess treatment outcomes in juvenile idiopathic arthritis (JIA)-associated uveitis and relapse rates upon discontinuation of immunomodulatory therapy (IMT). Methods: Medical records of patients with JIA-associated uveitis seen at the University of Illinois at Chicago and the F.I. Proctor Foundation uveitis clinics from September 14, 1988 to January 5, 2011 were reviewed. The main outcome was time to relapse after attempting to discontinue IMT.Results: Of 66 patients with JIA-associated uveitis, 51 (77%) received IMT as either sole or combination therapy. Of a total of 51, 41 (80%) patients achieved corticosteroid-sparing control. Attempts were made to discontinue treatment in 19/51 (37%) patients. Of a total of 19 patients, 13 (68%) attempting to discontinue IMT relapsed, with a median time to relapse of 288 days from the time of attempted taper/discontinuation (IQR: 108–338).Conclusions: Corticosteroid-sparing control of inflammation was achieved in the majority of patients; however, attempts to stop IMT were often unsuccessful. Close follow-up of patients after discontinuation of therapy is warranted.
KW - immunomodulatory therapy
KW - juvenile idiopathic arthritis-associated uveitis
KW - tumor necrosis factor-alpha inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85042235472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042235472&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1424341
DO - 10.1080/09273948.2018.1424341
M3 - Article
C2 - 29451845
AN - SCOPUS:85042235472
SN - 0927-3948
VL - 27
SP - 686
EP - 692
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 4
ER -